Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs used to treat people with type 2 diabetes. The drugs, classified as GLP-1 agonists, have also been used for weight loss ... The ...

Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said on Wednesday its net profit jumped 21 per cent in 2024 to 100 billion Danish ...

Ozempic (semaglutide) is a brand-name drug prescribed to treat certain conditions, such as type 2 diabetes. Ozempic has interactions with some other drugs, such as insulin, and certain supplements ...

This approval, along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular events in adults also with known heart ...

Novo Nordisk recently published favorable results from the FLOW renal outcomes trial, which found that Ozempic (semaglutide) 1.0 mg lowered the risk of kidney disease progression and kidney and ...

To use Ozempic, you must consult an endocrinologist or a healthcare professional specialising in diabetes management. The medication is administered via a pre-filled injection pen, usually once a ...

Some people using GLP-1 drugs like Ozempic for weight loss have a problem: Eggs are suddenly expensive and hard to find. Eggs aren't just big with fitness fans and Gaston from "Beauty and the Beast." ...

About 215,000 used GLP-1 drugs, while the rest were taking various other diabetes medications. Though semaglutides like Ozempic and Wegovy dominate the market in the U.S., Al-Aly and his team ...

A new study suggests that weight loss and diabetes treatment may represent only a small sample of the potential uses of GLP-1 drugs.

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous 96-week trial with 194 participants found no ...